Novo Nordisk's Oral Pivot Takes Shape as CagriSema Data Land and Orbis Deal Tops $1.4 Billion

Novo Nordisk signed a licensing deal with Orbis Medicines worth up to USD 1.4 billion and reported late-stage CagriSema weight-loss results.

Novo Nordisk used a packed stretch of announcements to press its case that the next chapter of the obesity and diabetes market will be written in tablets, not syringes. The Danish drugmaker capped the run with a development and licensing agreement signed on September 17 with Orbis Medicines, valued at as much as USD 1.4 billion, aimed at oral therapies for cardiometabolic disease. The pact bundles upfront and milestone payments, tiered royalties and a strategic equity investment in Orbis.

The deal lands one day after Novo disclosed a collaboration with Anthropic to speed drug development and advance AI-driven software tools, underscoring a leadership message that the company intends to compete head-on with Eli Lilly while pushing growth well past Wegovy.

CagriSema clears a high bar

At the center of the pipeline story sits CagriSema, which delivered late-stage clinical results on Monday. In the REIMAGINE-5 trial in diabetes patients, the candidate produced an estimated average weight loss of 12.4%, beating Eli Lilly's tirzepatide at the doses tested. A separate obesity study showed 21% weight reduction versus placebo at a 1.0 milligram dose, according to Reuters.

Those numbers give management a tangible counterweight to investor anxiety about the company's patent cliff and its ability to defend pricing power. The next hard test is already scheduled: the U.S. Food and Drug Administration is expected to rule in the fourth quarter on the CagriSema application for weight control.

Management lays out the long arc

Speaking at the company's Capital Markets Day, CEO Mike Doustdar set a target of bringing more than five blockbuster medicines to market by 2030, with pipeline revenue exceeding DKK 150 billion by 2035. Executives fielded pointed analyst questions on future pricing leverage and on transactions ahead of key patent expirations.

Beyond internal research, Novo is leaning on partnerships to open new drug classes. The Orbis tie-up is the clearest signal yet that oral formats are central to that effort, requiring substantial research and licensing outlays at a time when the payoff remains unproven.

Market skepticism lingers

Investors have yet to be convinced. The stock closed Tuesday at EUR 34.43, down 1.2%, after finishing the prior session at EUR 34.47 for a 1.0% decline. Year to date, the shares have shed 22%. During Monday's Capital Markets Day, the price fell by as much as 9%, a sign of how much doubt surrounds management's long-range assumptions.

The 52-week low of EUR 30.25 now serves as the line in the sand. Holding above it keeps the prospect of a bottoming pattern alive; a decisive break below could deepen the correction.

A wider footprint

Novo also extended its global partnership with UNICEF by four years, committing USD 18 million for 2026 through 2030. The program is designed to support prevention efforts in seven priority countries and give more than 80 million children a healthier start.

Whether the oral transition moves fast enough to offset margin pressure is the question that will define the coming quarters. If CagriSema clears the FDA and the pipeline gathers pace, Novo could cement its leadership. If rivals advance faster in oral delivery or discount more aggressively, the ambitious revenue targets will come under strain — and the loss of share in the high-margin core business becomes a real risk.